Cost and compliance may be colliding but, with the right strategy, organisations can navigate this intersection effectively.

Understanding that communication and transparency from experts are critical enablers for widespread confidence in AI is the ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

Grail is preparing to file for FDA approval of its Galleri test for detecting multiple cancers from a single blood test after ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. The announcement of the deal ...

AstraZeneca has forged a wide-ranging collaboration with Chinese biotech CSPC Pharma that will focus on the use of artificial intelligence (AI) to find new medicines across a range of diseases.

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...